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Abstract
Background: Dendritic cells (DCs) are professional antigen presenting cells that initiate specific immune responses 
against tumor cells. Transcription factor RBP-J-mediated Notch signaling regulates DC genesis, but whether this 
pathway regulates DC function in anti-tumor immunity remains unclear. In the present work we attempted to identify 
the role of Notch signaling in DC-mediated anti-tumor immune response.
Results: When DCs were co-inoculated together with tumor cells, while the control DCs repressed tumor growth, the 
RBP-J deficient DCs had lost tumor repression activity. This was most likely due to that DCs with the conditionally 
ablated RBP-J were unable to evoke anti-tumor immune responses in the solid tumors. Indeed, tumors containing the 
RBP-J deficient DCs had fewer infiltrating T-cells, B-cells and NK-cells. Similarly, the draining lymph nodes of the tumors 
with RBP-J-/- DCs were smaller in size, and contained fewer cells of the T, B and NK lineages, as compared with the 
controls. At the molecular level, the RBP-J deficient DCs expressed lower MHC II, CD80, CD86, and CCR7, resulting in 
inefficient DC migration and T-cell activation in vitro and in vivo. T-cells stimulated by the RBP-J deficient DCs did not 
possess efficient cytotoxicity against tumor cells, in contrast to the control DCs.
Conclusion: The RBP-J-mediated Notch signaling is essential for DC-dependent anti-tumor immune responses. The 
deficiency of RBP-J impairs the DC-based anti-tumor immunity through affecting series of processes including 
maturation, migration, antigen presentation and T-cell activation. The Notch signaling pathway might be a target for 
the establishment of the DC-based anti-tumor immunotherapies.
Background
Dendritic cells (DCs) are professional antigen presenting
cells (APCs) that initiate specific immune responses
against pathogens [1] and tumor cells [2]. Immature DCs
which locate in the tissues and the peripheral lymphoid
organs persistently surveillance the environment and rec-
ognize the invading pathogens and cell debris [3], and
capture antigens by phagocytosis, micropinocytosis, and
endocytosis. After the antigen recognition and uptake,
the immature DCs undergo a series of maturation events,
including the up-regulation of the major histocompatibil-
ity complex (MHC) II and the co-stimulatory molecules,
the secretion of cytokines, the outgrowth of dendrites,
and the modulation of chemokine receptor expression
profile accompanied by the migration into the T-cell
areas of the peripheral lymphoid organs [4]. The antigen-
loaded mature DCs can activate T-cells through the inter-
action between MHC II-peptide and T-cell receptor
(TCR) complex, and can activate B-cells [5] and NK-cells
[6] through specific ligands and cytokines expressed by
DCs. Based on the differential expression of cell surface
markers, DCs are grouped into two major classes includ-
ing conventional DCs (cDCs) [7] and plasmacytoid DCs
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Page 2 of 12(pDCs) [8]. cDCs are further subdivided into different
populations including the lymphoid tissue-resident DCs
and the peripheral tissues-located migrating DCs [1,4].
DCs play critical roles in the initiation, programming
and regulation of the anti-tumor immunity [9,10]. Never-
theless, as supported by both experimental studies and
clinical observations, the immune responses against
tumor cells are severely compromised in most, if not all,
progressing solid tumors. The tumor infiltrating myeloid-
derived suppressor cells (MDSCs), the tumor-associated
macrophages (TAMs) [11,12] and the cytokines secreted
by MDSCs and TAMs cooperatively create an immuno-
suppressive environment which leads to the suppression
of DC functions and the induction of regulatory T-cells.
Gerner et al reported that murine tumors were exten-
sively infiltrated by partially activated tumor-infiltrating
DCs (TIDCs) which had inefficient MHC II presentation
due to poor intrinsic protein uptake capability, resulting
in the inferior initiation of T-cell responses in the drain-
ing lymph nodes [13]. These resting, non-activated,
immature phenotypes of DCs have also been discovered
in cancer patients [14]. Moreover, DCs have been consid-
ered as a promising agent to generate effective anti-tumor
immune therapies, because DCs can be generated in large
numbers, and the cultured immature DCs could be con-
verted into mature DCs through the antigen loading with
peptides, recombinant proteins, tumor antigen-encoding
mRNA, and whole tumor cell lysates. These DCs can be
delivered to the tumor sites or the lymph nodes to acti-
vate T-cell responses against tumors [15]. However,
although the use of mature DCs as cellular vaccines
showed promising anti-tumor effects in many mouse
tumor models such as the B16 melanoma [16], the Lewis
lung cancer, the D2F2/E2 breast tumor and the EL4/E2
thymoma [17], the application of mature DCs in phase III
clinical trails in human cancer patients with prostate can-
cer [18] or melanoma [15] have largely failed. Therefore,
the fully understanding of the molecular mechanisms
regulating DC maturation and activation, which is still
obscure, is a prerequisite for the DC-based anti-tumor
therapies.
The Notch signaling pathway is an evolutionarily con-
served pathway that regulates development by participat-
ing in cell fate determinations and cell proliferation,
differentiation and apoptosis during embryonic and post-
natal stages [19]. There are four Notch receptors
(Notch1-4) and five ligands (Jagged1, Jagged2, and Delta-
like (Dll)1, 3, and 4) in mammals. After the triggering of
the Notch receptors by the binding of the Notch ligands,
the Notch intracellular domain (NIC) is cleaved by a pro-
teinase complex containing γ-secretase. NIC then trans-
locates into the nucleus, where it interacts with the
transcription factor C promoter-binding factor 1/recom-
bination signal-binding protein J/κ (RBP-J) [20,21]. This
protein complex will recruit other transcription co-acti-
vators, and transactivate the transcription of the target
genes such as the Hes family basic helix-loop-helix mem-
bers [22].
The Notch signaling plays an important role in the DC
genesis. Both of the Notch ligands Jagged1 and Dll1 can
activate Notch signaling in DCs, but their effect on DC
differentiation is different. Dll1-expressing fibroblasts
could induce DC differentiation, whereas Jagged1-
expressing fibroblasts inhibit DC differentiation and pro-
mote the accumulation of immature myeloid cells [23].
Similar results have also been reported by several other
groups. For example, Weijzen et al have shown that
Jagged1 is able to induce the maturation of the monocyte-
derived human DCs [24], while Ohishi et al have also
indicated that Dll1 promotes the DC differentiation
[25,26]. Cheng et al showed that the differentiation of
DCs was significantly impaired in mice expressing
Notch1 anti-sense RNA [27] and in a system involving
the Notch1 deficient embryonic stem (ES) cells [28]. The
deletion of RBP-J in DCs could result in the reduction of
the conventional DCs in the spleens of the mice. This
decrease is primarily limited to the CD8- DC subset in the
marginal zone of the spleens. As CD8- DCs in the mar-
ginal zone were found to reside in close contact with
Dll1-expressing cells, Dll1 could also be involved in the
loss of CD8- DCs [29]. However, Sekine et al showed that
the blocking of Dll1 alone had no significant effect on the
maintenance of CD8- DCs and the blocking of Dll1, Dll4,
Jagged1 and Jagged2 significantly decreased CD8- DCs
[30]. pDCs are different from cDCs in the phenotype and
the function. Several studies have reported that the dif-
ferentiation of pDCs could also be affected by Notch sig-
naling. Oliver et al reported that Dll1 could increase the
numbers of pDC through promoting the differentiation
rather than affecting the proliferation. A γ-secretase
inhibitor (GSI) could block this effect. But another group
reported the opposite result, showing that Dll1 could
block pDC development [31].
We have recently shown that the RBP-J-mediated
Notch signaling plays a critical role in the maturation of
the LPS-induced DCs [32]. In order to investigate
whether the Notch signaling participates in the DC-
mediated anti-tumor immunity, we established tumor-
bearing mouse models by using several mouse tumor cell
lines and RBP-J-deleted DCs [33]. We found that the
absence of RBP-J in DCs led to impaired DC-dependent
anti-tumor immune responses. We further demonstrated
that the RBP-J deficient DCs could not undergo a full
activation process upon tumor antigen stimulation,
which resulted in an inefficient T-cell activation and
tumor progress.
Feng et al. Molecular Cancer 2010, 9:90
http://www.molecular-cancer.com/content/9/1/90
Page 3 of 12Results
Tumor antigen-loaded spleen-derived DCs (SPDCs) repress 
tumor growth and tune up Notch signaling
Mice bearing a B16 malenoma tumor had an enlarged
spleen (data not shown), suggesting active immune
responses in the spleen. To evaluate the role of SPDCs in
anti-tumor immunity, we isolated CD11c+ SPDCs from
normal mice, pre-incubated with B16 crude tumor anti-
gens for 12 h, and then mixed SPDCs with B16 cells to
subcutaneously inoculate normal mice. We found that
compared with tumors without SPDCs, tumors inocu-
lated with SPDCs grew significantly slower regarding
tumor size and tumor weight (Fig. 1A and 1B), suggesting
that SPDCs had significant tumor-repressing activities.
We and others have recently shown that the RBP-J-
mediated Notch signaling is essential for the maturation
of peptide or LPS-stimulated DCs [24,32]. Thus, we
asked whether Notch signaling pathway was involved in
DC-mediated anti-tumor immunity. As an initial step to
explore this, the relative mRNA level of HES1 and HES5,
two major downstream molecules of Notch signaling, in
SPDCs was examined in tumor bearing mice. As shown
in Fig. 1C, compared with the control, SPDCs from
tumor-bearing mice had higher level of HES1 and HES5,
indicating that Notch signaling was activated in SPDCs of
tumor-bearing mice.
RBP-J deficient DCs are unable to repress tumor growth 
when co-inoculated with tumor cells in mice
To investigate the role of Notch signaling in the DC-
dependent anti-tumor immunity, we used the RBP-J con-
ditional deletion mouse model [33]. RBP-J-floxed mice
were mated with the Mx-Cre transgenic mice. In the
adult RBP-J+/f-MxCre (RBP-J+/-) and RBP-Jf/f-MxCre
(RBP-J-/-) mice, the injection of the interferon (IFN)-α
inducer poly(I)-poly(C) induced the deletion of the DNA-
binding domain of the floxed RBP-J alleles. The deletion
was almost complete in hematopoietic cells including
DCs [[32,33], and data not shown]. We then established
tumor-bearing mouse models to investigate the effects of
RBP-J deletion on the anti-tumor immunity of DCs.
SPDCs of the RBP-J deleted mice and the control mice
were co-injected subcutaneously with four types of the
mouse tumor cell lines, including B16, H22, S180, and
LLC, into wild type C57BL/6 mice. The growth of the
tumors was monitored with two standards, including the
tumor volume and the tumor weight. From the 5th day
after the inoculation, the tumor volume was followed up
to the 17th day. As shown in Fig. 2A, compared with the
tumors containing RBP-J+/- DCs, the tumors containing
RBP-J-/- DCs grew significantly faster in volume. Even in
the S180 sarcoma, of which the tumor size decreases
from 9th day after the inoculation, the tumors with the
RBP-J deficient DCs were constantly larger than the
tumors with the control DCs at all time points examined.
Moreover, on day 17 after the inoculation, tumors were
dissected and the tumor weight was measured. In all of
the four types of tumors, the tumors containing RBP-J-/-
DCs were significantly heavier than the tumors contain-
ing the control DCs (Fig. 2B). Fig. 2C shows representa-
tive tumors dissected on the day 17 after the co-
inoculation of tumor cells with different types of DCs.
These results indicated that the RBP-J deficient DCs had
remarkably reduced tumor-suppressing activities. RBP-
J+/- DCs were indistinguishable from the wild type DCs in
their anti-tumor activities in this experiment system (data
not shown).
SPDCs contain several subtypes of DCs, and RBP-J
deletion might influence the differentiation of a specific
subtype [29,30]. We examined different subpopulations
of SPCDs from RBP-J deficient mice, or irradiated mice
after accepting BM cells from RBP-J deficient mice. As
shown in additional file 1, while CD8- DCs decreased
most remarkably, all subpopulations of SPDCs decreased
in the absence of RBP-J. Therefore, attenuated anti-tumor
activity of SPDCs could be more likely attributed to
Figure 1 SPDCs repress the growth of B16 tumors when co-inoc-
ulated with tumor cells. (A) The B16 tumor cells (5 × 106) were mixed 
without or with wild type SPDCs (1 × 106), and were injected subcuta-
neously into normal mice. The tumor volume was monitored every 2 
days from the 5th day after the inoculation, by measuring the tumor 
length (L) and short (S) with a sliding caliper. Tumor volume = L × S2 × 
0.51. (B) The tumors were dissected 13 days after the inoculation, and 
the tumor weight was compared. (C) qRT-PCR analysis. DCs in the 
spleens of wild type and B16 tumor-bearing mice were sorted by anti-
CD11c magnetic beads. The Notch downstream genes were analysed 
by qRT-PCR, with β-actin as an internal control. Bars, means ± SD, * P < 
0.05 (n = 4).
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DCs [24,32].
Decreased infiltration of T, B and NK cells in the tumors 
containing the RBP-J-/- DCs in mice
DCs function in the initiation of the anti-tumor immune
responses through the recruitment and the activation of
T-cells [34], B-cells [5] and NK cells [35] into tumors. So,
we examined these populations of immune cells in
tumors inoculated with the RBP-J deficient and the con-
trol DCs in mice. The B16, LLC, H22 and S180 tumor
cells were mixed with the RBP-J deficient and the control
SPDCs, and were injected subcutaneously into normal
mice. Immune cells infiltrating the tumors were exam-
ined 17 days after the inoculation by FACS analysis. We
found that in the B16 melanoma and the H22 hepatocar-
cinoma, the infiltration of CD4+ T-cells, CD8+ T-cells,
CD19+ B-cells and NK1.1+ NK-cells were significantly
lower in tumors containing the RBP-J deficient DCs than
in the tumors containing the control SPDCs (Fig. 3A). In
the S180 sarcoma, while the infiltrating CD4+ T-cells and
CD19+ B-cells were significantly lower in tumors with
RBP-J-/- DCs, the decease of CD8+ T-cells and NK-cells
appeared not so impressive (see additional file 2). In LLC,
only the CD4+ T-cells decreased significantly in the
tumors co-inoculated with the RBP-J deficient DCs (see
additional file 2). These results suggested that the RBP-J
deficient DCs had weaker capacity in the activation and/
or recruitment of at least some populations of immune
cells into solid tumors.
Inefficient activation of immune cells in the draining lymph 
nodes of mice bearing tumors containing RBP-J deficient 
DCs
Immune responses taking place in the draining lymph
nodes are critical for the establishment of adaptive immu-
Figure 2 Tumor growth in mice inoculated with the tumor cells mixed with RBP-J+/- and RBP-J-/- SPDCs. (A) The B16, H22, S180 and LLC tumor 
cells (5 × 106) were mixed with RBP-J+/- and RBP-J-/- SPDCs (1 × 106), and were injected subcutaneously into normal mice. The tumor volume was mon-
itored every 2 days from the 5th day after the inoculation. (B) The tumors were dissected 17 days after the inoculation, and the tumor weight was 
compared. Bars, means ± SD. *P < 0.05. n = 4 in B16; n = 3 in H22; n = 3 in S180; n = 3 in LLC. (C) Representative tumors were compared between the 
two groups.
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tumor antigens, DCs migrate into the draining lymph
nodes where DCs present the specific tumor antigens to
the naïve T-cells to initiate the adaptive immune
responses. We therefore examined the immune responses
in the draining lymph nodes of B16 malenoma tumors.
The draining lymph nodes of the B16 melanoma contain-
ing RBP-J-/- DCs were significantly smaller in size than
those of the tumors containing the RBP-J+/- DCs (data not
shown). Consistently, the total cell number of the drain-
ing lymph nodes of the B16 melanoma containing RBP-J-/
- DCs was significantly smaller than that of the tumors
containing RBP-J+/- DCs (Fig. 3B). We further analyzed
the number of different populations of cells in the drain-
ing lymph nodes of melanoma tumors by flow cytometry.
The results showed that while the ratio between different
cell populations was not significantly skewed (data not
shown), the absolute cell numbers of the CD4+ T-cells,
CD8+ T-cells, CD19+ B-cells and NK1.1+ NK-cells were
significantly lower in the draining lymph nodes of the B16
melanoma containing RBP-J-/- DCs (Fig. 3C). Moreover,
we performed the DNA content analysis of cells in the
draining lymph nodes by FACS. We found that in the
draining lymph nodes of the B16 melanoma containing
RBP-J-/- DCs, cells with hyper-diploid DNA amount
increased about 77.5%, but cells with hypo-diploid
amount of DNA increased 422.6%, compared with the
controls (Fig. 3D). These data suggested that the cell
apoptosis in the draining lymph nodes of the RBP-J-/- DC-
Figure 3 Infiltration of CD4+, CD8+, CD19+ and NK1.1+ cells in the tumors and draining lymph nodes of the mice bearing B16 and H22 tu-
mors. The tumor cells were mixed with RBP-J+/- and RBP-J-/- SPDCs, and were injected subcutaneously into normal mice. (A) The tumors were dissect-
ed on the 17th day after the inoculation, and the single-cell suspensions were prepared for FACS analyses. The number of CD4+, CD8+, CD19+ and 
NK1.1+ cells in 1 g of tumor tissues was calculated based on FACS. (B) The draining lymph nodes were dissected, and the total cell number in the 
lymph nodes was compared between the RBP-J-/- and RBP-J+/- groups. (C) FACS was carried out to compared the number of CD4+, CD8+, CD19+ and 
NK1.1+ cells in the draining lymph nodes of mice bearing melanoma containing the RBP-J deficient SPDCs or the control SPDCs. Bars, means ± SD. n 
= 4. (D) DNA content analysis of the cells isolated from the draining lymph node of the mice bearing melanoma containing the RBP-J deficient DCs 
or the control DCs. Pictures represent one set of four independent experiments.
Feng et al. Molecular Cancer 2010, 9:90
http://www.molecular-cancer.com/content/9/1/90
Page 6 of 12containing B16 melanoma was much higher than that of
the controls.
Decreased CCR7 expression and migration ability of RBP-J 
deficient DCs
We have recently shown that the disruption of RBP-J in
BM-derived DCs down-regulated the expression of the
chemokine receptor CXCR4 and the chemotactic migra-
tion of DCs [32]. We then examined the expression of
chemokine receptors on the tumor antigen-loaded DCs
derived from the spleens of the RBP-J deficient and the
control mice. Crude tumor antigens were prepared using
the B16 melanoma cells, and were loaded onto DCs iso-
lated from the spleens of the RBP-J deficient and the con-
trol mice. The ability of antigen uptake by DCs appeared
comparable between the RBP-J deficient DCs and the
control DCs (data not shown). Interestingly, we found
that the CXCR4 expression was not changed significantly
when compared between RBP-J+/- and RBP-J-/- DCs (data
not shown), but the expression of CCR7, a critical
chemokine receptor involved in the migration of the anti-
gen-activated DCs, was significantly down-regulated (Fig.
4A and 4B). Then, we performed the in vivo migration
assay to analyze the migration ability of RBP-J-/- DCs.
DCs isolated from the spleens of the RBP-J+/- and RBP-J-/-
mice were labeled with CFSE, and were loaded with the
B16 tumor antigens. DCs were injected subcutaneously at
the left lower abdomen of the wild type C57BL/6 mice.
DCs arriving at the draining lymph nodes were examined
by FACS 12 h later. As shown in Fig. 4C, significantly less
RBP-J-/- DCs arrived at the draining lymph nodes, com-
pared with RBP-J+/- DCs. These data suggested that the
disruption of RBP-J in the SPDCs damaged their migra-
tion capacity after the tumor antigen uptake.
RBP-J deficient DCs show attenuated expression of 
molecules related to antigen presentation capacities after 
the loading of tumor antigens
The antigen presentation by DCs is persuaded by differ-
ent groups of molecules including MHC I and II and the
co-stimulatory molecules. We next examined the expres-
sion of these molecules by the antigen-stimulated or the
antigen-unstimulated RBP-J+/- and RBP-J-/- DCs. The
average expression of MHC II was lower on the RBP-J
deficient DCs than the control DCs, regardless with or
without antigen stimulation (Fig. 5A and 5B, upper pan-
els). The expression of CD80 and CD86 co-stimulatory
molecules were also decreased in the RBP-J-/- DCs com-
pared with the RBP-J+/- DCs after the tumor antigens
stimulation (Fig. 5A and 5B, middle and lower panels).
These results suggested that RBP-J-/- DCs were not fully
activated after the tumor antigen stimulation.
RBP-J deficient DCs show multiple defects in the activation 
of anti-tumor T-cells
We next characterized the T-cell activation ability of the
RBP-J deficient and the control SPDCs loaded with B16
tumor antigens. Naïve CD3+ T-cells were obtained from
wild type C57BL/6 mice by the negative magnetic selec-
tion and were labeled with the CFSE dye. The T-cells
were co-cultured with the RBP-J deficient or the control
DCs, which had been loaded with the crude B16 tumor
antigens. Five days after the starting of the co-culture, the
proliferation of T-cells was analyzed for the CFSE dilu-
tion by flow cytometry. As shown in Fig. 6A, both of the
RBP-J+/- and RBP-J-/- DCs could stimulate T-cell prolifer-
ation, but the RBP-J-/- DCs showed a significantly
decreased ability in the stimulation of the T-cell prolifera-
tion as compared to the control DCs.
To explore this phenomenon in vivo, we performed the
BrdU incorporation assay. The B16 tumor antigen-loaded
SPDCs were injected subcutaneously at the left lower
abdomen of the mice, and BrdU was injected intra-peri-
toneally on the fifth day after the injection of SPDCs.
Seven days later, the mice were sacrificed. The total cell
number of the draining lymph nodes of the mice accept-
ing tumor antigen-loaded RBP-J deficient SPDCs was
Figure 4 Cell migration assay. (A, B) SPDCs with different genotypes 
were co-cultured with the B16 tumor antigens, and the expression of 
CCR7 was analyzed by flow cytometry. The mean fluorescence intensi-
ty (MFI) of CCR7 expression was compared between groups. Bars, 
means ± SD. *P < 0.05. n = 3. (C) SPDCs with different genotypes were 
stained with CFSE, and were incubated with the B16 tumor antigens. 
SPDCs (1 × 106) were then injected subcutaneously at the left lower 
abdomen, and the draining lymph nodes were dissected 12 h later. 
CFSE positive DCs were detected by FACS, and the number of CFSE 
positive DCs in the draining lymph nodes was calculated based on 
FACS. Bars, means ± SD. n = 3.
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draining lymph nodes were further analyzed for the DNA
content and the BrdU incorporation by the staining with
FITC-anti-BrdU and APC-anti-CD3. The results showed
that compared with the controls, fewer cells from the
draining lymph nodes of the mice accepting RBP-J defi-
cient SPDCs were in the S or G2+M phase of the cell
cycle (data not shown). Consistently, the BudU incorpo-
ration analysis of the CD3+ T-cells confirmed that the T-
cells in the draining lymph nodes of the mice accepting
the tumor antigen-loaded RBP-J deficient SPDCs showed
less DNA synthesis (Fig. 6C). These results suggested that
tumor antigen-loaded RBP-J deficient SPDCs had less
activity in the stimulation of T-cells in vivo.
We then examined the secretion of cytokines by the T-
cells stimulated with the RBP-J+/- and RBP-J-/- SPDCs
loaded with the tumor antigens. Cytoplasmic staining
and ELISA showed that the RBP-J deficient SPDCs stimu-
lated less IFN-γ secretion by T-cells, as compared with
the control SPDCs (Fig. 6D and 6E). IL-4 secretion by the
T-cells stimulated with RBP-J-/- DCs was also lower than
T-cells stimulated with the control SPDCs (Fig. 6F and
6G), suggesting that the reduced IFN-γ production by the
RBP-J-/- SPDC-stimulated T-cells was not due to a bias of
Th1 versus Th2 polarization.
To access the ability of the RBP-J deficient and the con-
trol SPDCs to activate cytotoxic T-cells, naïve T-cells
were co-cultured with the B16 tumor antigen-loaded
SPDCs. After co-cultured for 3 days, the activated T-cells
were mixed with B16 tumor cells, and specific cytotoxic-
ity was assessed by the LDH assay. As shown in Fig. 6H,
the specific tumor cell lysis ability of the T-cells activated
by RBP-J-/- SPDCs was significantly lower than that of the
T-cells activated by RBP-J+/- SPDCs. We also performed
in vivo CTL assay to investigate the function of the T-
cells activated by different SPDCs. Normal mice were
vaccinated with the B16 tumor antigen-loaded RBP-J-/-
and RBP-J+/- SPDCs. Seven days after the vaccination, T-
cells were collected from the draining lymph nodes by
negative magnetic selection, and were co-cultured with
the B16 tumor cells. We found that the specific tumor cell
lysis ability of the T-cells from the RBP-J-/- SPDC-vacci-
nated mice were significantly lower than that of the T-
cells from the control SPDC-vaccinated mice (Fig. 6I),
Figure 5 FACS analysis of MHC II, CD80 and CD86 expressions. SPDCs with different genotypes were co-cultured with the B16 tumor antigens, 
and the expression of MHC class II, CD80 and CD86 was analyzed by flow cytometry (A). MFI of MHC class II, CD80 and CD86 expression was compared 
between groups (B). Bars, means ± SD. n = 3.
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smaller draining lymph nodes and spleens as compared
with the controls (data not shown). Therefore, we con-
cluded that the RBP-J deficient SPDCs had less capacity
to activate T-cells, concerning the cell proliferation,
cytokine production, and cytotoxicity.
Discussion and Conclusion
As the strongest professional antigen presenting cells,
DCs play critical roles in the activation of the anti-tumor
immunity. Much attention has been paid to the utiliza-
tion of DC vaccines to initiate efficient tumor specific
effector T-cells to inhibit tumor growth. Indeed, in 1990s,
many investigators have attempted to use tumor antigen-
Figure 6 Decreased proliferation and cytotoxicity of T-cells stimulated with RBP-J deficient SPDCs. (A) FACS analysis. The CFSE-labeled T-cells 
(1 × 106) were co-cultured with SPDCs (2 × 105) pre-incubated with B16 tumor antigens for 5 days, and the T-cell proliferation was analyzed. (B) SPDCs 
(1 × 106) pre-incubated with the B16 tumor antigens were injected subcutaneously at the lower left abdomen of normal mice. The draining lymph 
nodes were dissected 7 days later, and the total cell number in the lymph nodes was compared between the RBP-J-/- and RBP-J+/- groups. (C) BrdU 
incorporation assay. SPDCs (1 × 106) pre-incubated with the B16 tumor antigens were injected subcutaneously at the left lower abdomen of normal 
mice. BrdU was injected intraperitoneally twice per day from the 5th day for 3 days. BrdU+CD3+ cells in the draining lymph nodes were detected by 
flow cytometry 7 days later. (D-G) Cytokine production. Naïve T-cells were co-cultured with SPDCs pre-loaded with B16 tumor antigens for 72 h. Cy-
toplasmic staining was performed to analyze IFN-γ(D) and IL-4 (F) production of T-cells by flow cytometry. ELISA was carried out to detect IFN-γ (E) 
and IL-4 (G) secretion in the supernatants. (H) CTL assay. Normal T-cells were co-cultured with SPDCs pre-loaded with B16 tumor antigens for 3 days. 
Live B16 melanoma cells were then co-cultured with the activated T-cells at different ratios of 1:10, 1:20, 1:40, 1:80 for 36 h. LDH in the supernatants 
was detected by using an LDH kit. (I) CTL assay. DCs (1 × 106) pre-loaded B16 tumor antigens were injected subcutaneously at the left lower abdomen 
of normal mice. Seven days later, the draining lymph nodes were dissected and single-cell suspensions were obtained. T-cells were magnetically sort-
ed and were co-cultured with live B16 melanoma cells at different ratios of 10:1, 20:1, 40:1, 80:1 for 36 h. LDH activity in supernatants was detected. 
Bars, means ± SD. n = 3.
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after the initial success with the preventive and therapeu-
tic DC vaccination in mouse models [36]. Although the
use of mature DCs as cellular vaccines had provided
encouraging and exciting anti-tumor effects in many
mouse tumor models [16,17], the applications of mature
DCs in the phase III clinical trails in human cancer
patients with prostate cancer [18] or melanoma [15] have
largely failed. Obviously, the understanding of the molec-
ular mechanisms regulating DC maturation is essential
for the DC-based anti-tumor therapies.
Notch signaling pathway might influence tumor growth
in multiple ways [37]. In this study, we showed that the
disruption of the transcription factor RBP-J, which is crit-
ical in the mediation of the canonical Notch signaling
pathway, attenuated the DC-dependent anti-tumor
immunities. By using co-inoculation of four types of
tumor cells with DCs in mice, which mimic the injection
of activated DCs directly into tumor tissues, we found
that tumors co-inoculated with the RBP-J deficient DCs
were significantly bigger than tumors containing the con-
trol DCs. The inefficient infiltration of the immune cells
including T-cells, B-cells and NK cells into the tumor tis-
sues containing RBP-J-/- DCs further suggested that DCs
with Notch signaling deficiency could not prime adaptive
immune responses to tumor cells. Although previous
studies have shown that Notch signaling affects the devel-
opment, differentiation and function of DCs, the results
reported here directly showed that the Notch signaling
pathway is important for DCs to evoke efficient anti-
tumor immune responses in mice.
The phenotypes of the tumor antigen-loaded RBP-J
deficient DCs are reminiscent of immature DCs. DCs are
derived from hematopoietic stem cells accommodated in
BM. Immature DCs are generated through a series of
complicated differentiation steps in BM, and are exported
into the blood stream and thereafter enter into the sec-
ondary lymphoid organs and the peripheral tissues. Nor-
mally, upon the uptaking and processing of tumor
antigens in the peripheral tissues, immature DCs mature
into fully activated DCs, by the gain of migration capac-
ity, the outgrowth of dendrites, and the up-regulated
expression of the MHC molecules and the co-stimulatory
molecules. Mature DCs subsequently migrate into the
draining lymph nodes where they present the processed
antigens to resting T lymphocytes in the shape of pep-
tide-MHC complex, to generate immune responses
against pathogens and tumors. In vitro and in vivo studies
have shown that DCs loaded with tumor antigens could
be activated to initiate anti-tumor immune responses. In
our study reported here, DCs isolated from the spleen of
mouse were activated by the incubation with the crude
tumor antigens, and these DCs appeared to have the abil-
ity to activate anti-tumor immunities. While the RBP-J+/-
DCs showed the properties of mature DCs upon antigen
loading, RBP-J-/- DCs appeared immature in several
aspects. First, the migration of the tumor antigen-loaded
RBP-J-/- DCs was impaired. We analyzed the expression
of chemokine receptors including CCR7 and CXCR4, and
found that although the CXCR4 level was almost the
same in both RBP-J-/- and RBP-J+/- DCs after tumor anti-
gen loading, the expression of CCR7 was significantly
lower in RBP-J-/- DCs. CCR7 has been shown to play
important roles in the migration of mature DCs. It is
likely that the lowered expression of CCR7 mediated the
reduced migration of RBP-J deficient DCs from the
tumor tissues to the draining lymph nodes, but more
detailed molecular experiments are needed to clarify the
mechanism controlling the chemokine receptor expres-
sion in DCs. Second, the expression of MHC II was
weaker in the RBP-J deficient DCs as compared with the
control DCs. The up-regulation of the MHC II expression
is a critical marker of DC maturation. DCs in our experi-
mental system appeared heterogenous concerning the
MHC II expression. In the tumor antigen-unloaded and
loaded RBP-J-/- DCs, the level of MHC II was lower than
the control DCs. Third, the level of co-stimulatory mole-
cules, CD80 and CD86, was significantly lower on the
tumor antigen-loaded RBP-J-/- DCs than that on the con-
trol DCs. This is especially true for the expression of
CD80. Lowered expression of the co-stimulatory mole-
cules also supports that RBP-J deficient DCs are imma-
ture after tumor antigen loading. Last but not least, RBP-J
deficient DCs showed lowered capacity in the stimulation
of T-cells. Our data showed that both in vitro and in vivo,
the tumor antigen-loaded DCs had attenuated capacity of
stimulating the T-cell proliferation, cytokine production
and cytotoxicity. Interestingly, in the draining lymph
nodes of the mice bearing the B16 melanoma containing
RBP-J-/- DCs, higher proportion of apoptotic cells was
observed, as compared with the controls. This suggested
that RBP-J-/- DCs might have immuno-repressive activity,
but further studies are needed to access cell proliferation
and apoptosis in different populations of cells. The
molecular mechanisms, such as the components of crude
tumor antigen preparations and the involvement of TLRs,
are now under investigation, although the expression of
PD-L1 and PD-L2 on DCs was not changed (data not
shown). Because no difference was observed in the rate of
tumor antigen phagocytosis between the RBP-J deficient
and the control DCs (data not shown), the immature phe-
notypes of the RBP-J deficient DCs could be attributed to
some intrinsic defects in the maturation of the tumor
antigen-loaded DCs. However, we could not exclude a
possibility that RBP-J deficient DCs represent another
population of DCs, such as regulatory DCs. Further stud-
ies with DC-specific RBP-J deletion mouse models [29]
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clarify this point.
B-cells and NK cells were also activated by DCs. Qi et al
reported that lymph node B-cells could be activated by
antigen-bearing DCs by two-photon intravital imaging
[38]. Kijima et al reported that NK-cells could be acti-
vated by DCs and that Jagged2-Notch interaction is very
critical in this process [6]. Our results also showed that
the proportion and absolute number of B cells and NK
cells were significantly lower in RBP-J-/- DCs, indicating
that Notch signaling is also important for DCs to activate
B-cells and NK cells in the anti-tumor immunity.
Taken together, the Notch signaling pathway could
affect the differentiation and the maturation of DCs, and
the deficiency of Notch signaling pathway could impair
DC-based anti-tumor immunity. Our results suggest the
important role of Notch signaling pathway in the DC-
based anti-tumor immunity. Therefore, the Notch signal-
ing might be a potential target to interfere the DC-based
anti-tumor immunotherapies. However, detailed studies
about the mechanisms of the regulation of DCs by Notch




Mice were maintained in the specific pathogen-free (SPF)
conditions on the C57BL/6 background. The RBP-J-
floxed (RBP-Jf) mice were as described [33] and were
crossed with the Mx-Cre transgenic mice to get the RBP-
Jf/f-MxCre and RBP-J+/f-MxCre (as controls) mice (hence,
referred as RBP-J-/- and RBP-J+/-, respectively). The mice
were genotyped by the polymerase chain reaction (PCR)
[33]. Four-week-old mice were injected intraperitoneally
with 300 μg/100 μl poly(I)-poly(C) (Sigma, St. Louis,
MO) for four times at 2-day intervals and were then
injected with the same dosage of poly(I)-poly(C) for
another eight times at 1-week intervals (twelve injections
in total). All animal experiments were approved by the
Animal Experiment Administration Commission of
Fourth Military Medical University.
Cell lines and cell culture
Lewis lung carcinoma (LLC), mouse S180 sarcoma
(S180), mouse H22 hepatocarcinoma (H22), and mouse
melanoma (B16) cell lines were gifts from CH Shi. All of
the tumor cell lines were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum, 2
mM L-glutamine, 50 IU/ml penicillin, and 50 μg/ml
streptomycin sulfate.
DCs were separated by anti-CD11c magnetic beads
(Miltenyi Biotec GmbH, Germany) from mouse spleen
cell suspensions according to the instructions of the man-
ufacturer, and were cultured in RPMI 1640 medium as
described previously [32].
Preparation of crude tumor antigens [39]
The cultured LLC, S180, H22 and B16 cells were har-
vested by using a cell scraper, washed in phosphate-buff-
ered saline (PBS), and were resuspended in PBS at
approximately 5 × 107/mL. The cells were disrupted by
freeze and thaw for 5 times, followed by centrifugation in
a benchtop microcentrifuge for 10 min at 10,000 rpm.
The supernatants were transferred into sterilized Eppen-
dorf tubes, and were stored at -80°C for later use. In some
experiments, B16 cells were labeled with the Dio Cell-
Labeling Solution (Invitrogen, Carlsbad, CA) according
to the manufacturer's protocol, and were then used for
the preparation of the Dio-labeled B16 tumor antigens.
Tumor-bearing mouse models
Tumor cells (5 × 106) were injected subcutaneously into
the normal mice. Five days after the initial inoculation,
tumor growth was monitored every 2 days by measuring
the tumor length (L) and short (S) with a sliding caliper.
The tumor size was calculated as L × S2 × 0.51. Seventeen
days after the initial inoculation, the tumors were excised
and the tumor weight was measured. The tumor tissues
and the tumor draining lymph nodes were minced and
were filtrated through a nylon filter for flow cytometry
analysis.
Flow cytometry
Single cell suspensions were resuspended with PBS con-
taining 2% fetal calf serum and 0.05% NaN3 and were
counted. Cells (3-5 × 105) were stained with antibodies at
4°C for 30 min before being analyzed using a FACSCali-
bur (BD Immunocytometry Systems, San Jose, CA). Dead
cells were excluded by the propidium iodide (PI) gating.
Data were analyzed using the CellQuest software. PE-
anti-CD4 (RM4-5), APC-anti-CD8 (53-6.7), APC-anti-
CD19 (1D3), biotinylated anti-NK1.1 (PK136), APC-anti-
CD3 (145-2C11), biotinylated anti-IAb (KH174), and
FITC-anti-BrdU were purchased from BD PharMingen
(San Diego, CA). FITC-anti-CD11c (N418), biotinylated
anti-CD11c, FITC-anti-CD80 (16-110A1), PE-anti-CD86
(GL-1), and Streptavidin-APC were products of BioLeg-
end (San Diego, CA), and Streptavidin-PE and biotiny-
lated anti-CCR7 (4B12) were from eBioscience (San
Diego, CA).
Migration assay
DCs (1 × 106) were separated by anti-CD11c magnetic
beads from the mouse spleen cell suspensions, and were
labeled with CFSE. DCs were co-cultured with the B16
tumor antigens at a ratio of 1:2 for 12 h at 37°C, and were
then collected and resuspended in 200 μl PBS, and were
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mice. The mice were sacrificed 12 h later, and the drain-
ing lymph nodes were collected for FACS analysis.
T-cell proliferation assay
DCs (2 × 105) were seeded in 96-well plates and were co-
cultured with B16 tumor antigen for 12 h, followed by
medium exchanging. Congeneic T-cells (1 × 106) were
isolated by negative selection using magnetic beads,
labeled with carboxyfluorescein diacetate succinimidyl
ester (CFSE), and were co-cultured with B16 tumor anti-
gen-loaded DCs. Five days later, T-cell proliferation was
detected by FACS.
For the in vivo assay, DCs (1 × 106) were sorted by using
the anti-CD11c magnetic beads, and were loaded with
the B16 tumor antigens for 12 h at 37°C. The tumor anti-
gen-loaded DCs were injected subcutaneously into nor-
mal congenic mice at the left lower abdomen. On the 5th
day, the mice were injected intraperitoneally with 1 mg/
100 μl BrdU twice per day for three days, with PBS as a
control. The mice were sacrificed on the 7th day and the
draining lymph nodes were dissected. Single cell suspen-
sions were prepared and were stained for CD3 and BrdU
(anti-BrdU-FITC) according to the manual of the BrdU
Flow kit provided by the manufacturer (BD Biosciences-
Pharmingen).
Enzyme-linked immunosorbent assay (ELISA)
Culture supernatants were collected and were used to
detect the level of cytokines using different assay kits
(Bioresun, China). OD450 was recorded using a spectro-
photometer, and was compared between groups.
CTL assay
DCs were loaded with the B16 tumor antigens for 12 h,
and were then co-cultured with negatively selected T-
cells (1 × 106) in 96-well plates for 72 h. The culture
supernatants were discarded, and the B16 tumor cells
were added into the wells with different ratios of 1:10,
1:20, 1:40, 1:80 to T-cells. After co-culturing for 36 h in
the serum free RPMI 1640, the supernatants were col-
lected for the examination of cell death by using a colori-
metric lactate dehydrogenase (LDH) assay kit (Cayman
Chemical Company, Ann Arbor, MI) according to the
manufacturer's manuals.
For the in vivo assay, the B16 tumor antigen-loaded
DCs (1 × 106) were injected subcutaneously into normal
C57BL/6 mice at the left lower abdomen. On the 7th day
after the injection, the mice were sacrificed and the drain-
ing lymph nodes were recovered. Single cell suspensions
were prepared, and T-cells were negatively selected by
using magnetic beads. The T-cells (1 × 106) were then co-
cultured with the target B16 tumor cells at different ratios
of 10:1, 20:1, 40:1, 80:1 in 96-well plates. The cells were
co-cultured in the serum free RPMI 1640 for 36 h, and
the supernatants were collected for the detection of the
cell death by using the LDH assay kit (Cayman Chemical
Company).
Analysis of DNA content
Cells were collected from the draining lymph nodes of
the tumor-bearing mice or the mice inoculated with the
tumor antigen-loaded DCs. The cells (1 × 106) were fixed
with 70% ethanol for 20 min at room temperature, and
were then washed once with PBS. After being resuspened
in 500 μl of 20 μg/ml PI solution containing 0.1% (v/v)
Triton X-100 (Sigma) and 0.2 mg/ml DNase-free RNase
A (Sigma), the cells were analyzed by FACS.
Quantitative real time RT-PCR
Total RNA was extracted from SPDCs using TRIzol
reagent (Invitrogen, Carlsbad, CA) according to the man-
ufacturer's instructions. Complementary DNA was pre-
pared using a reverse-transcription kit from TOYOBO
(Osaka, Japan). Real-time reverse-transcription PCR (RT-
PCR) was performed using a kit (SYBR Premix EX Taq,
Takara) and the ABI PRISM 7300 real-time PCR system,
with β-actin as an internal control. Primers used in real-
time PCR were as follows: β-actin forward: CATCCG-
TAAAGACCTCTATGCCAAC, β-actin reverse: ATG-
GAGCCACCGATCCACA, HES1 forward:
GCAGACATTCTGGAAATGACTGTGA, HES1 reverse:
GAGTGCGCACCTCGGTGTTA; HES5 forward: AAA-
GACGGCCTCTGAGCAC, HES5 reverse: GGTGCT-
TCACAGTCATTTCCA.
Statistics
Statistical analysis was performed with the SPSS 12.0 pro-
gram. Results were expressed as means ± SD. Compari-
sons between groups were undertaken using the unpaired
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